What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

Victoza (liraglutide) and Ozempic (semaglutide) are two injectable drugs used to treat people with type 2 diabetes. The drugs, classified as GLP-1 agonists, have also been used for weight loss in ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Is that the best course of action? Let's find out ... which includes drugs like Zepbound and Mounjaro, didn't grow as fast as it anticipated in the fourth quarter. Besides the fact that the ...

The body does not absorb berberine well, limiting its ability to affect body weight significantly. However, berberine may enhance a weight-loss routine, given its safety and tolerability. Still, ...

In line with that, our review highlights the well-accepted mechanisms of action and resistance to the therapy and discusses the progress that has been made toward successfully overcoming this ...